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Abstract
A major challenge to developing a successful HIV vaccine is the vast diversity of viral sequences, yet it is generally assumed
that an epitope conserved between different strains will be recognised by responding T-cells. We examined whether an
invariant HLA-B8 restricted Nef90–97 epitope FL8 shared between five high titre viruses and eight recombinant vaccinia
viruses expressing Nef from different viral isolates (clades A–H) could activate antiviral activity in FL8-specific cytotoxic T-
lymphocytes (CTL). Surprisingly, despite epitope conservation, we found that CTL antiviral efficacy is dependent on the
infecting viral isolate. Only 23% of Nef proteins, expressed by HIV-1 isolates or as recombinant vaccinia-Nef, were optimally
recognised by CTL. Recognition of the HIV-1 isolates by CTL was independent of clade-grouping but correlated with virus-
specific polymorphisms in the epitope flanking region, which altered immunoproteasomal cleavage resulting in enhanced
or impaired epitope generation. The finding that the majority of virus isolates failed to present this conserved epitope
highlights the importance of viral variance in CTL epitope flanking regions on the efficiency of antigen processing, which
has been considerably underestimated previously. This has important implications for future vaccine design strategies since
efficient presentation of conserved viral epitopes is necessary to promote enhanced anti-viral immune responses.
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Introduction
One of the greatest challenges in developing an effective T-cell
based vaccine against HIV-1 is its high genetic variability [1]. Group
M HIV-1 has expanded globally into 15 major clades, sub-clades and
several interclade circulating recombinant forms. These continually
evolving HIV-1 clades differ by over 30% in envelope amino acid
sequences and viral isolates within the same clade may also differ by
up to 15% [2]. The high rate of mutation from error-prone reverse
transcription combined with replicative ability enables HIV-1 to
adapt rapidly to immune and drug pressure, with the generation of
multiple genetically distinct quasispecies within infected individuals.
HIV-1 vaccines must overcome these obstacles to induce protective
immunity against heterologous viral variants [3].
A critical component of HIV-1 control during the acute phase is
the cytotoxic T-lymphocyte (CTL) response [4,5]. Therefore, many
current vaccine strategies focus on identifying immunogens that elicit
effective T-cell immunity against a diverse range of viral variants and
characterising HIV-1 specific CTL responses in order to define the
immune correlates of protection [5]. To counteract antigenic
diversity, there is an increasing interest in developing HIV vaccines
which elicit CTL responses to conserved epitopes, centralised
sequences or immunogenic regions of high inter-clade homology
[6,7,8,9,10]. Currently, the interferon gamma (IFNc) producing
ELISpot assay is frequently used to quantify the breadth and
magnitude of CTL responses [11], using peptides matched to
consensus virus sequence or occasionally to autologous infecting virus
sequence [12] [13]. Most data show that CTL recognition of epitope
peptides is very sensitive to any change in the epitope peptide [13,14].
Thus the HLA type of the patient imprints changes on the sequence
of the infecting virus, generally thought to be within the epitopes that
have stimulated CTL responses [15,16]. However, while CTL may
efficiently recognise exogenously loaded synthetic peptide matched to
HIV-1 clade variants, it has been found that this does not necessarily
correlate with CTL antiviral activity against HIV-1 infected cells
displaying endogenously derived peptides [17]; for example, the
artificial peptides may be added at non-physiological concentrations.
Therefore, conventional peptide-based assays may over-estimate the
ability of CTL to cross-recognise variant epitopes [18]. The use of
exogenous synthetic peptides to quantify CTL responses may alsofail
PLoS Pathogens | www.plospathogens.org 1 May 2011 | Volume 7 | Issue 5 | e1001341to detect differences in the antiviral efficacy of CD8 T-cells that reflect
variation in antigen processing efficiency within HIV-infected cells
[19,20]. Remarkably, whilst much research has focused on
recognition of exogenously added peptide epitopes, CTL recognition
of virus-infected cells has been examined relatively rarely, and there
has been no analysis of CTL recognition of invariant epitopes shared
by diverse viral isolates and clades.
The present study arose from the observation that CD8+ Tc e l l s
specific for the highly conserved HLA B8 restricted Nef epitope
FLKEKGGL (FL8) failed to recognize HLA B8 positivecellsinfected
with several HIV-1 isolates. Previously it has been shown that escape
mutationscan occur in the epitope flanking regions through impaired
processing and presentation [21,22,23,24,25,26,27], however, such
studies have focused predominantly on a single viral isolate, mostly in
circulating virus rather than selected viral strains in individual
patients, or focused on classical escape mutation [28]. Therefore a
range of HIV-1 isolates and vaccinia viruses expressing different Nef
proteins, each of which shared this conserved epitope, were used to
test responses from a set of CTL clones isolated from HLA B8+
patients. Overall, we evaluated CTL recognition and antiviral
efficacy induced by a total of thirteen viral isolates containing the
same conserved epitope. Surprisingly, only a small proportion (23%)
of these HIV-1 isolates induced optimal CTL recognition and
antiviral efficacy. We found that variations in the flanking region had
a profound effect on the presentation of this epitope, and viral isolates
w i t h i nt h es a m eH I V - 1c l a d ew e r ed i f f e r e n t i a l l yr e c o g n i z e db yF L 8 -
specific CTL clones. Furthermore, we identified a phenylalanine
motif in the FL8-epitope flanking regions of four HIV-1 isolates that
led to an altered pattern of cleavage by the immunoproteasome that
correlated with loss of CTL recognition.
Results
CTL recognition of exogenous synthetic peptide does
not correlate with CTL antiviral activity against
endogenous peptide presented de novo on the surface
of HIV-infected cells
In conventional IFNc ELISPOT and chromium release assays,
we assessed three Nef FL8-specific CTL clones and four control
Gag EI8-specific CTL clones for their recognition of HLA-B8
+
matched C8166 target cells pulsed with peptides at different
concentrations to measure functional avidity (the peptide concen-
tration that gives 50% maximum effect). The FL8-specific and
EI8-specific CTL clones had comparable levels of functional
avidity, measured by IFNc release (Figure 1A) and in a lytic assay
(Figure 1B). In addition, there were no significant differences
(p.0.05) observed between FL8- and EI8- specific responses in the
lysis assay at all peptide concentrations tested. This suggested that
both peptides would be equally recognised in HLA-B8 target cells
infected with HIV-1.
We then compared CTL recognition of synthetic Nef FL8
peptide pulsed exogenously onto the surface of uninfected C8166
targets with CTL antiviral efficacy against endogenously derived
FL8 epitope presented on the cell surface of HIV-1HXB2 infected
C8166 targets. Surprisingly, FL8-specific CTL did not recognise
or mount an antiviral response against the virus-infected target
cells.
In a Viral Suppression Assay (VSA), the panel of FL8- and EI8-
specific CTL clones were co-cultured for four days with C8166
target cells infected with HIV-1HXB2 at five E:T ratios, after which
suppression of viral replication in the supernatant was quantified
by measuring the level of Gag p24 by ELISA; and suppression of
HIV-infected targets (via CTL lysis or non-cytolytic inhibition) was
measured using intracellular p24 staining. Despite the similar
functional avidity in peptide based assays, at a low infectious titre
of virus, EI8-specific CTL exhibited superior suppression of viral
replication compared to FL8-specific CTL when p24 was
measured in supernatant by ELISA (Figure 2A). At all E:T ratios
tested, co-culture with EI8-specific CTL resulted in undetectable
levels of p24 Gag (below the ELISA threshold of 10 pg/ml) whilst
viral suppression by FL8-specific CTL was negligible when
compared to wells of virus-infected targets in the absence of
CTL. Analysis of suppression at a high infectious titre showed
similar results, with negligible suppression of virus-infected cells by
FL8-specific T-cells at all E:T ratios tested (ranging from 37–
89 ng/ml with a mean p24 of 62 ng/ml in the absence of CTL)
(Figure 2B). Subsequent analysis of the p24 stained cells showed a
similar pattern (Figure 2C). At the 1:1 and 1:4 ratios, the control
EI8 specific CTL clones demonstrated effective inhibition of viral
replication, although they were unable completely to abrogate
infection, whilst FL8-specific CTL did not differ from the controls
in their suppression of viral infection at all three ratios tested. 2-
way ANOVA with bonferroni post-test confirmed a statistically
significant difference (p,0.01 or p,0.001) between Nef-specific
and Gag-specific clones at each E:T ratio in the ELISA.
We also developed a Live Virus Elispot (LVE) assay to assess
IFNc release by CTL exposed to HIV-infected target cells, as a
marker of CTL antiviral activity over time. C8166 target cells were
infected with HIV-1HXB2 and incubated for a period of 24, 48, 72
and 96 hours at 37uC. At each respective time point, the HIV-
infected cells were co-cultured with HLA-matched FL8- and EI8-
specific CTL clones on a pre-coated IFNc ELISpot plate. Again,
FL8-specific CTL did not mount an IFNc response at any of the
time points tested (Figure 2D). In contrast, the EI8 epitope was
recognised by the EI8-specific CTL clones, which generated a
detectable IFNc response that was significantly different (p,0.001)
between FL8- and EI8-specific clones at 48, 72 and 96 hours post-
infection in a 2-way ANOVA with bonferroni post-test.
The three Nef FL8-specific clones were generated from three
separate HLA-B8
+ long-term non-progressors (LTNP) and control
Gag EI8-specific clones were generated from one HLA-B8
+ LTNP
patient. The use of this pre-screened panel of T-cell clones
removes the complexity of different TCR affinities, and thus
Author Summary
Oneofthegreatestchallengesto developingan effectiveHIV
vaccine is the ability of HIV to rapidly alter its viral sequence.
Such variation in viral sequence enables the virus to
frequently evade recognition by the host immune system.
To counteract this problem, there has been increasing
interest in developing HIV vaccines that target T-cell
responses to the regions of the virus that are highly
conserved between strains of HIV. However, previous studies
have focused on identifying amino acid variation predomi-
nantlywithin a single viral isolate,or have focusedon classical
within-epitope escape mutation. Our study assessed T-cell
recognition of a conserved epitope shared by a total of 13
HIV strains. Strikingly, we show that only a small proportion
of the viral strains were effectively recognised and targeted
by the T-cells. In contrast,differences in amino acid sequence
in the region flanking the epitope impaired the intracellular
processing and presentation of epitope in the majorityof HIV
strains tested. Thus, our findings highlight that a large
proportion of HIV strains may evade epitope-specific T-cell
recognition despite absolute epitope conservation. This has
important implications for both vaccine design and evalua-
tion of vaccine efficacy.
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responses.
Significant variation in CTL antiviral efficacy to a
conserved Nef epitope shared between HIV isolates and
clades
To investigate whether CTL recognition and antiviral activity to
a conserved epitope may depend on the infecting HIV-1 isolate,
we chose five high titre HIV viruses (three clade B laboratory
strains and two clade A isolates) that share the invariant Nef FL8
epitope for testing via in vitro Viral Suppression Assays (VSA) and
Live Virus ELISPOTS (LVE). FL8 is an immunodominant
epitope that is highly conserved amongst HIV-1 Group M isolates
in the Los Alamos National Laboratory (LANL) HIV sequence
database. Proviral DNA for each virus was isolated from control
wells containing infected C8166 targets in the absence of CTL,
PCR amplified and sequenced to confirm the presence of the
invariant FL8 epitope. The results from both assays and viral
sequencing are summarised in Table 1.
Data from the viral suppression assay for each virus shows
differing FL8-specific CTL antiviral activity for the different virus
isolates, despite sharing the conserved FL8 epitope (Figure 3). FL8
specific CTL suppressed both clade A viral isolates HIV-192UG029
and HIV-193RW024, as well as Clade B HIV-1MN, to below the
threshold of detection (10 pg/ml) in the p24 ELISA (Figure 3C).
However, clade B HIV-1HXB2 (as characterised before in
Figure 2A) and clade B HIV-189.6 were not suppressed by FL8-
specific CTL at any of the effector:target (E:T) ratios tested, and
were not statistically different (p.0.05) when compared to wells of
virus-infected cells in the absence of CTL. Similar trends were
obtained when analysing the corresponding infected co-cultures
from the VSA (Figure 3B). In HIV-192RW024 infected target cells,
FL8 specific CTL reduced infection from 9% to ,1% whilst a
reduction was also observed in HIV-192UG029 infected cells at all
three E:T ratios tested, which were significantly different (p,0.01)
from control wells of infected cells in the absence of CTL. The
clade B virus HIV-1MN was also efficiently suppressed by FL8 and
EI8 CTL. However, FL8-specific CTL exerted no significant
antiviral efficacy against HIV-1HXB2 or HIV-189.6 infected target
cells, suggestive of impaired intracellular FL8 epitope processing
and presentation. Similar result was observed while using HIV-
1HXB2 and MN infected HLA B8+ PBMCs as target cells in VSA
(Figure S2).
Differential CTL antiviral activity to the FL8 epitope between
viral isolates was also observed in the Live Virus Elispots (LVE)
assay (Figure 3C). FL8-specific CTL demonstrated a strong IFNc
response with an average magnitude of 46–101 SFUs at 96 hours
post-infection against endogenously presented FL8 peptide by cells
infected with clade A isolates HIV-192UG029 and HIV-192RW024
respectively. In contrast, a varied FL8-specific CTL response was
observed against clade B infected cells, with a mean of 65 SFUs
recorded for HIV-1MN, but 0 SFUs at 96 hrs post-infection for
both HIV-1HXB2 and HIV-189.6. Further LVE studies were
conducted at 6 and 12 hours post-infection to assess ‘early’ CTL
recognition of endogenous Nef and Gag epitopes but no IFNc
responses were observed.
All high titre viruses were tested in parallel with the same panel
of three highly avid FL8-specific clones and four control EI8-
specific clones with the same results. All five viruses were CXCR4-
tropic, able to replicate efficiently and were pathogenic, as
confirmed by syncytia formation with 6–20% of C8166 cells
(p24+/CD4+) infected by Day 4 in the absence of CTL. A low
MOI was chosen for physiologic relevance to an in vivo setting,
with ,20% infection observed, comparable to other SIV and
HIV- based viral suppression assays [21,29]. However, similar
results were also obtained at a higher MOI, so viral titre does not
appear to impact upon the patterns observed (as observed in
figure 2B). Furthermore, since HIV-1HXB2, MN and 93RW024
contained a conserved HLA-A24 restricted RW8 Nef epitope, we
were also able to utilise CTL clones specific for RW8 to confirm
that these viruses were able to present Nef derived peptides to
CTL and were not simply Nef-deficient (Figure S1). Interestingly,
although there is a general trend towards higher p24 at the lower
E:T ratios with the control gag clones, and with the Nef clones to a
lesser extent, overall the E:T ratio appears to have limited
influence in the VSA. This is in accordance with the results from a
similar assay [30] and may be attributable to the use of CTL
clones that were pre-selected for their high avidity and ability to
Figure 1. Nef FL8-specific and Gag EI8-specific CTL clones demonstrate similar functional avidity. Synthetic FL8 and EI8 peptides were
exogenously titrated on uninfected CD4+ Tcell line C8166 with their respective panel of FL8- and EI8-specific clones in a conventional IFNc ELISPOT at
an E:T ratio of 400:20000 (A) and 51Cr release assay at an E:T ratio of 40000:5000 (B) per well. FL8- specific clones are shown in red and control EI8-
specific clones are shown in blue. The standard error results represent three independent experiments.
doi:10.1371/journal.ppat.1001341.g001
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polyclonal populations with differing avidity). It should also be
noted that our control Gag EI8 clones specific to EIYKRWII were
chosen as an internal control as they had similar functional avidity
for the clade A intra-epitopic variant DI8 (DIYKRWII) when
tested with peptides in the IFNc ELISPOT and chromium release
assays (data not shown). However, these Gag-specific CTL were
unable to respond to DI8 targets within the clade A viruses HIV-
193RW024 and HIV-192UG029 in Figure 3, due to more
efficient immunoproteasomal processing for EI8 than DI8 (data
not shown); however they still acted as good internal controls for
clade B infections.
Overall, our data from the viral suppression assays and live virus
ELISPOTS clearly demonstrate that efficient CTL antiviral
activity is heavily dependent on the infecting HIV-1 isolate, which
cannot be accurately predicted from epitope sequence conserva-
tion alone or by clade-grouping.
Significant variation in CTL recognition of a conserved
FL8 epitope from recombinant vaccinia viruses
expressing Nef from eight different viral isolates (clades
A–H)
We also infected HLA-B8 B-cells with recombinant vaccinia
virus constructs expressing HIV-1 Nef (rVV-Nef) from eight viral
isolates, each from a different group M clade (for simplicity
abbreviated by their clade reference): HIV-192UG037.1(A), HIV-
1MN (B), HIV-196ZM651 (C), HIV-194UG114.1 (D), HIV-1CM235-32
(AE), HIV-193BR020 (F), HIV-192NG83.2 (G) and HIV-190CF056 (H).
The rVV-Nef expressing cells were co-cultured with FL8-specific
CTL in two assays; a
51Cr-release assay and IFNc ELISPOT. The
results from both assays and the pre-determined rVV-Nef
sequences are summarised in Table 1.
In the
51Cr-release assay, striking differences were observed in
the level of CTL-induced lysis of cells infected with rVV-Nef from
different viral isolates, which could be categorised into three
distinct groups based upon their mean percentage lysis. Only in
cells infected with rVV-Nef-D was the proportion of lysed cells
(70%) comparable to peptide-pulsed targets (75%) indicative of
optimal abundance of endogenously derived FL8 for efficient
recognition and lysis (Figure 4B). Subsequent analysis confirmed
that there was no significant difference between rVVNef-D and
the control in an ANOVA (p.0.05). In contrast, infection with
viral isolates B, C, F and H resulted in reduced CTL recognition,
with only 20–70% lysis compared to the peptide control, whilst no
significant CTL killing (.20% lysis) was observed for isolates A,
AE and G, suggestive of impaired or abolished FL8 processing and
presentation. Concordant results were observed in the IFNc
ELISPOT (Figure 4A). Only isolate D elicited levels of IFNc
release (132 SFCs) similar to the peptide control (135 SFCs). In
contrast, infection with B, C, F and H showed intermediate levels
of 67, 23, 57 and 34 SFCs respectively and less than 10 SFCs for
A, AE and G. In total, seven rVV-Nefs elicited CTL antiviral
responses that were significantly different (p,0.01 or p,0.001)
from the CTL response to the FL8 peptide control. These data
support the isolate-specific nature of CTL antiviral efficacy,
despite epitope conservation between viruses.
To ensure similar levels of Nef protein expression in these assays,
rVV infection used the same plaque forming unit (pfu) titre and a
CTL clone specific to a conserved Nef epitope HLA-A3 QK10 was
utilised as an internal control. The strong CTL response to
endogenous QK10 peptide presented by rVV-A, AE and G in the
chromium release assay confirmed that these rVV efficiently
infected the BCL targets and were not Nef-defective (Figure S1).
Figure 2. Nef FL8-specific CTL clones show negligible anti-viral
efficacy to HIV-1HXB2 infected cells. In the Viral Suppression Assay
(VSA), the CD4+ T-cell line C8166 was infected separately with low titre
(A) and high titre (B) HIV-1HXB2 and co-cultured with a panel of FL8- and
EI8-specific clones at several E:T ratios for 4 days and the viral
supernatant was subsequently assayed by p24 ELISA. The low-titre
infected co-culture was also assayed by intracellular p24 staining (C). In
the Live Virus ELISPOT (LVE) assay, C8166 was infected with HIV-1HXB2
for a period of 24, 48, 72 and 96 hours post-infection. At each
respective time point, infected cells expressing endogenously derived
epitopes were co-cultured with their respective panel of FL8- and EI8-
specific CTL clones on a pre-coated IFNc ELISPOT for 6 hours at an E:T
ratio of 400:20000 (D). FL8- specific clones are shown in red and control
EI8-specific clones are shown in blue. The standard error represents
each clone tested in triplicate for every respective E:T ratio or time point
and is representative of three independently performed assays.
doi:10.1371/journal.ppat.1001341.g002
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infected with HIV-1 high titre isolates or recombinant
vaccinia viruses expressing HIV-1 isolate specific Nef
protein
To verify that the striking differences in CTL antiviral activity to
a conserved epitope observed in Figure 3 and 4 were not
attributable to differing Nef-induced down-regulation of surface
MHC class I expression by the various virus isolates [31,32], we
infected target cells with virus and assessed HLA-B8 surface
expression using a HLA-B8 specific monoclonal antibody. We
compared HLA-B8 expression in HLA-B8
+ targets infected with
our five high titre HIV-1 isolates (48 hours post-infection) and
eight rVV-Nef constructs (4 hours post-infection), and also utilised
three HLA-B8
2 negative targets as a negative control.
Our results showed that although down-regulation of HLA-B8
surface expression was observed in the high titre virus infected cells
when compared with uninfected or vaccinia-infected targets, there
was no marked variation in HLA-B8 between the five high titre
HIV-infected target cells (Figure 5A). Furthermore, there was no
marked variation in HLA-B8 expression between the eight rVV-
infected target cells (Figure 5B). However, we acknowledge that
the direct measurement of HLA-B8 expression may vary between
experiments. Whilst Lewis et al controlled for this with internal
standards [33], Nef-deleted viruses were not available for
comparison with our wild-type viruses. Alternatively, we utilised
B8-restricted Gag CTL controls in our viral suppression assays
and live virus Elispots, since any effect of Nef mediated down-
regulation of HLA-B8 ought to apply equally to this epitope and
not be restricted to Nef epitopes. The CTL recognition of the Gag
epitope was the same for the viruses tested, even when Nef
recognition differed markedly. Together, these data therefore
demonstrate that Nef-mediated down-regulation of HLA-B8 is not
responsible for diminished CTL recognition of the conserved FL8
epitope on cells infected with HIV-1HXB2 and 89.6 isolates, or with
rVV-Nef constructs A, AE and G.
Proteasomes and immunoproteasomes are important in
the endogenous generation of the Nef FL8 epitope
From the above results it seemed likely that differences in
antigen processing might explain the failure of CTL to recognise
cells infected with some of the virus isolates and rVV-Nef.
Intracellular peptide processing is a multi-step pathway and amino
acid variations within epitopes and their flanking regions can affect
any step of this complex cascade [34], which includes proteasomal
or immunoproteasomal cleavage, TAP mediated transport to the
ER lumen and N-terminal trimming by aminopeptidases.
Alternatively, other proteases such as tripeptidyl peptidase II
(TPPII) may act independently or in combination with the
Table 1. Despite the identical FL8 epitope, only a small proportion (23%) of these HIV-1 isolates induced optimal CTL recognition
and antiviral efficacy.
High Titre HIV
Isolates Clade Viral Sequence for FL8 and flanking region
Viral Suppression
Assay
Live Virus
ELISPOT
HIV-192UG029 A VGFPVRPQVPLRPMTYKGAVDLSHFLKEKGGLDGLIYSRKRQEI
LDLWVYNTQGYF
++ ++
HIV-193RW024 A VGFPVRPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIYSRRRKD
ILDLWVYHTQGFF
+++ +++
HIV-1HXB2IIIB B VGFPVTPQVPLRPMTYKAALDLSHFLKEKGGLDGLIYSQ
KRQDILDLWVYHTQGYF
22
HIV-1MN B VGFPVRPQVPLRPMTYKAALNLSHFLKEKGGLDGLIYSQKR
QDILDLWVYHTEGYF
+++ ++
HIV-189.6 B VGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLDGLIHSQKRQDI
LDLWVYHTEGYF
22
rVV-Nef HIV
Isolates Clade
Viral Sequence for FL8 epitope and
flanking region
51Cr-release
Assay IFNc ELISPOT
HIV-192UG037 A VGFPVRPQVPLRPMTYKAAFDLGFFLKEKGGLDGLIYSKKRQE
ILDLWVYHTQGYF
22
HIV-1MN B VGFPVKPQVPLRPMTYKAALDLSHFLKEKGGLDGLIYSQKRQ
DILDLWVYHTQGYF
++ ++
HIV-196ZM651 C VGFPVRPQVPLRPMTYKAAVDLSFFLKEKGGLEGLIYSKKRQEIL
DLWVYHTQGFF
++
HIV-194UG114 D VGFPVRPQVPLRPMTYKEAVDLSHFLKEKGGLEGLVWSPKRQ
EILDLWVYHTQGFF
+++ +++
HIV-1CM235 A/E VGVPVRPQVPLRPMTYKGAFDLSFFLKEKGGLEGLIYSKRRQE
ILDLWVYNTQGFF
22
HIV-193BR020 F VGFPVRPQVPLRPMTYKGAVDLSHFLKEKGGLEGLIYSKRRQE
ILDLWVYHTQGYF
++ ++
HIV-192NG083 G VGFPVRPQVPLRPMTYKAAFDLSFFLKEKGGLDGLIYSKRRQ
DILDLWVYNTQGFF
22
HIV-190CF056 H VGFPVRPQVPLRPMTYKGAFDLSHFLKEKGGLDGLIYSKQR
QDILDLWVYNTQGYF
++ 2
The results from the Viral Suppression Assay and Live Virus Elispot in Figure 3 and IFNc ELISPOT and CTL Lysis assays in Figure 4 are summarised with +++ for optimal,
++ for impaired, + for severely impaired and 2 for abolished epitope processing and CTL antiviral efficacy.
doi:10.1371/journal.ppat.1001341.t001
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PLoS Pathogens | www.plospathogens.org 5 May 2011 | Volume 7 | Issue 5 | e1001341Figure 3. Despite the identical FL8 epitope, only 3/5 viruses tested induced effective FL8-specific antiviral responses. Viral
Suppression Assay including p24 ELISA of viral supernatant (A) and intracellular p24 staining of infected co-culture (B), and the Live Virus Elispot (C).
FL8- specific CTL responses are shown in red and control EI8-specific CTL responses are shown in blue. Each assay was independently performed at
least 3 times for each virus.
doi:10.1371/journal.ppat.1001341.g003
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a pivotal role in the generation of the immunodominant HLA-A3
Nef QK10 epitope [35], which is located 8 amino acid residues
downstream from the HLA-B8 Nef FL8 epitope.
To test the importance of different components of the antigen
processing machinery on the generation and presentation of FL8
on the infected-cell surface, we chose two viruses that elicited a
dominant FL8 response; high titre HIV-192UG029 and rVV-D
(HIV-194UG114). Infected target cells were treated with inhibitors
to block proteasome and immunoproteasome (Epoxomicin),
aminopeptidase activity (Bestatin) and tripeptidyl-peptidase II
activity (AAF-CMK) at appropriate concentrations. Controls
included inhibitor treated cells pulsed with peptide (both HIV-
infected and uninfected) to ensure that the read out was not altered
by inhibitor-induced cell death.
The addition of epoxomicin to high titre HIV-192UG029 infected
cells in a modified Live Virus ELISPOT intracellular antigen
processing inhibition assay (IAPIA) completely abolished recogni-
tion of FL8 at 10 mM (Figure 6A). In contrast, addition of bestatin
and AAF-CMK, even at high concentrations of 10–100 mM, had
little impact on CTL recognition. A similar pattern was observed
when the same three inhibitors were added to BCL infected with
rVV-D (HIV-194UG114) in modified chromium release IAPIA
(Figure 6B). The addition of epoxomicin at 10 mM and 1 mM
reduced CTL lysis by 82% and 53% respectively, whilst addition
of Bestatin and AAF-CMK at 10 mM had minimal effect. The
marked difference in CTL lysis at 100 mM is likely to represent
partial inhibition of proteasomal activity when used at high
concentrations. Overall, in contrast to the Nef QK10 epitope [35],
the result with AAF-CMK showed that TPPII is not involved in
the FL8 processing pathway for the two viruses tested.
Together, these inhibition assays clearly demonstrate that
proteasomes and immunoproteasomes play a pivotal role in the
endogenous processing of the HLA-B8 FL8 epitope which is
required to initiate efficient CTL antiviral activity against HIV-
192UG029 and HIV-194UG114 infected targets. Therefore, as a first
key step in the processing pathway and in accordance with the
antigen processing literature (reviewed in [36,37]), the cleavage
specificities of the immunoproteasomes and proteasomes in
particular are likely to have a significant impact on epitope
generation correlating with subsequent epitope abundance on the
cell surface [38].
Virus-specific polymorphisms in the FL8 flanking region
alter CTL epitope antigen processing
Since the FL8 epitope is conserved between all HIV-1 isolates
tested in previous assays, we next investigated whether viral isolate-
specific polymorphisms flanking FL8 could modulate the antigen
processing efficiency of this epitope. We hypothesised that
processing and production of the FL8 epitope may be more
efficient in cells infected with clade A isolates HIV-192UG029 and
HIV-193RW024, and clade B HIV-1MN, whilst impaired antigen
processing could account forpoorCTL recognition of clade B HIV-
1HXB2 and HIV-189.6 viruses in Figure 3. Two 25-mer oligopeptides
were therefore synthesised to span FL8 (Nef90–97) and its flanking
region (Nef82–106), one corresponding to HIV-1HXB2 and the other
corresponding to HIV-192UG029. The two oligopeptides differed in
the flanking region by 3 amino acids including position 83 (glycine/
alanine), 85 (valine/leucine), and 104 (arginine/glutamine). Of
these amino acid polymorphisms, the former two can be considered
conservative variations, while replacement of arginine by glutamine
leads to loss of a basic residue and replacement by an uncharged
side chain. To test whether these residues affected antigen
processing by the immunoproteasome, which is most commonly
involved in CTL epitope generation, each oligopeptide was
incubated with purified immuno-20S-proteasome (i20S) for 0, 10,
40 and 70 minutes. The peptide fragments resulting from
immunoproteasomal digestion were identified using tandem mass
spectrometry. Since immunoproteasomes and proteasomes rarely
produce the exact 8–11mer peptide, but instead generate longer
Figure 4. 7/8 recombinant vaccinia viruses expressing Nef (rVV-Nef) from different viral isolates show impaired or abolished
antiviral activity. A HLA-B8 B-cell line was infected separately with each rVV-Nef and co-cultured with an FL8-specific clone in a IFNc ELISPOT at an
E:T ratio of 400:20000 (A) and
51Chromium release assay at an E:T ratio of 40000:5000 per well (B). The standard error results represent three
independent experiments.
doi:10.1371/journal.ppat.1001341.g004
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terminus, we defined an ‘epitope precursor’ as a peptide fragment
containing the intact FL8 epitope that is extended at the amino (N)
terminus and carboxyl (C) terminus, and a ‘correct epitope pre-
cursor’ as a peptide that is extended only at the N-terminus and
correctly cleaved at the C-terminus.
Both oligopeptides showed strikingly different digestion patterns
(Figure 7) when digested at these time points. Oligopeptide HIV-
Figure 5. No marked difference in HLA-B8 surface expression between target cells infected by individual HIV isolates or rVV-Nef
constructs. C8166 targets were infected with the five high titre viruses for 48 hours post-infection (A) or HLA-B8+ BCL were infected with eight
recombinant vaccinia viruses expressing Nef for 4 hours post-infection (B). HLA-B8 surface expression was assessed using a HLA-B8 specific
monoclonal antibody via flow cytometry. HLA-B8 uninfected cells are shown in black and HLA-B8- negative cells are shown in grey dashed lines as
negative controls.
doi:10.1371/journal.ppat.1001341.g005
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peptides, of which one was a correct C-terminally cleaved peptide
(KGAVDLSHFLKEKGGL) (Figure 8A). Although mass spec-
trometry is only semi-quantitative, UPLC-MS
E analysis at each
time point showed that this C-terminally cleaved peptide was
present as early as 10 minutes post i20S digestion and increased in
Figure 6. Immunoproteasomes and proteasomes are pivotal to the generation of endogenously processed FL8 epitope. In the
intracellular antigen processing inhibition assay (IAPIA), HLA-B8 targets were pre-treated with Epoxomicin (immunoproteasome and proteasome
inhibitor), Bestatin (aminopeptidase inhibitor) and AAF-CMK (TPPII protease inhibitor). Target cells were then infected with HIV-192UG029 for 36 hours
post-infection and co-cultured with a FL8-specific CTL clone on an IFNy ELISPOT at an E:T ratio of 400:20000 per well (A) or infected with rVV-D for
4 hours and then co-cultured with a FL8-specific CTL clone in a chromium release assay at an E:T ratio of 40000:5000 per well (B). Red bars represent
endogenously derived FL8 peptide for CTL recognition. Blue bars represent exogenously added synthetic FL8 peptide for CTL recognition as an
internal control against inhibitor-induced cell death in infected target cells, (with blue bars in the ELISPOT standardised relative to maximum
endogenous FL8 SFUs in the absence of inhibitors). The addition of each inhibitor to virally-infected cells was performed in triplicate.
doi:10.1371/journal.ppat.1001341.g006
Figure 7. Oligopeptides derived from HIV-192UG029 and HIV-1HXB2 showed strikingly different digestion patterns. A pair of 25-mer
oligopeptides representing HIV-192UG029 and HIV-1HXB2 Nef82–106 was incubated with purified immunoproteasome for 0, 10, 40 and 70 minutes and
peptide fragments were identified using tandem mass spectrometry. For immunoproteasomal digests analysed at 70 minutes; peptides with an
individual ions score .30 are displayed. The cleavage sites within each peptide sequence are indicated by black arrows, with bold arrows indicating
frequent cleavage. The conserved FL8 epitope sequence is highlighted in red and virus-specific polymorphisms in the FL8 flanking sequence are
highlighted in blue.
doi:10.1371/journal.ppat.1001341.g007
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contrast, digestions of oligopeptide HIV-1HXB2 produced several
FL8 containing precursor peptides, but these contained substantial
N- and C-terminal extensions, and were only 3 amino acids
shorter at most than the original 25-mer oligopeptide. None of the
precursor peptides generated from digestion of oligopeptide HIV-
1HXB2 contained the correct C-terminal cleavage for FL8.
Critical phenylalanine residues in the N-terminal FL8
flanking region diminish epitope generation
Because of the large number of viral isolate-specific polymor-
phisms in the different viruses tested, it is difficult to define
accurately which amino acid polymorphism(s) in the flanking
regions present in different HIV-1 isolates critically impair
immunoproteasomal cleavage of FL8. We speculated that one or
several amino acid polymorphisms may act in tandem to alter
cleavage patterns. Since most of the flanking amino acid
differences were in the N-terminal part of the FL8 epitope, we
‘‘swapped’’ the N-terminal sequence of the FL8 epitope region
from the HIV-192UG029 virus that is recognized by CTL with the
sequence derived from the rVV-Nef-A(HIV-192UG037) virus that is
not recognized (see Table 1 and Figure 9A) to create a ‘‘hybrid’’
FL8 epitope precursor. When digested by proteasomal proteolysis
and analysed by UPLC-MS
E, no correct C-terminal cleavage was
observed, indicating that the N-terminal region of the FL8 epitope
is critical for this cleavage step. We therefore further examined the
polymorphisms observed in the PCR-derived sequence ‘tracked’ to
either superior or abolished antiviral efficacy in our assays
(Table 1). Interestingly, polymorphisms in our live viral sequences
did not track to CTL antiviral efficacy. Conversely, we noted that
the presence of a phenylalanine at position 89 immediately
adjacent to the N-terminus of the FL8 epitope and an additional
phenylalanine at position 85, correlated with abolished CTL
antiviral efficacy in three rVV isolates; A, AE and G. Variation of
N- and C-terminal epitope flanking residues can influence the
length and nature of epitope precursors that are generated [39]
[40] [41] and the immunoproteasome is known to have a
preference for cleaving after hydrophobic residues [42]. Thus,
this motif is likely to have a pronounced impact on FL8 cleavage
patterns. We therefore repeated the in vitro proteasomal digestion
assay to test whether this phenylalanine motif may play a key role
in modulating epitope processing. We chose two previously studied
viruses that exhibited contrasting epitope generation in digests
(associated with contrasting CTL antiviral efficacy); HIV-192UG029
and rVV-Nef-A(HIV-192UG037). Previous digestion of the HIV-
192UG029 derived precursor peptide generated a correct C-
terminally cleaved FL8 pre-cursor that was present in large
quantities. In contrast, digestion of the HIV-192UG037 derived
Figure 8. Oligopeptide HIV-192UG029 produced a correct C-terminally cleaved peptide (KGAVDLSHFLKEKGGL). (A) MS/MS spectrum of
the peptide KGAVDLSHFLKEKGGL with an observed mass (m/z) of 425.49Da. The assigned b and y fragment ions are indicated. (B) Generation of the
peptide KGAVDLSHFLKEKGGL in proteasomal digest. Ion extract chromatograms showing the precursor peptide [M+4H]
4+ (m/z 425.49Da)
demonstrating the accumulation of this proteolysis product over time.
doi:10.1371/journal.ppat.1001341.g008
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no FL8-containing pre-cursors at any of the time points tested
(Figure 8). Therefore, we took the HIV-192UG029 sequence
(KGAVDLSHFLKEKGGLDGLIYSRKR) and designed two
new 25-mer oligopeptides; the first in which we substituted the
basic histidine residue with a large hydrophobic phenylalanine at
position 89 immediately adjacent to FL8 (HIV-192UG029+1:
KGAVDLSFFLKEKGGLDGLIYSRKR) and an additional sub-
stitution at position 85 (HIV-192UG029+2: KGAFDLSFFLK-
EKGGLDGLIYSRKR) in which hydrophobic valine was re-
placed with a hydrophobic phenylalanine. The original
oligopeptide and two new oligopeptides were then digested with
immunoproteasome for 0, 10, 40, and 70 minutes and peptide
fragments were identified using tandem mass spectrometry
(Figure 9). The insertion of the phenylalanine motif markedly
altered the pattern of immunoproteasomal cleavage. Whilst the
digestion of the original HIV-192UG029 sequence generated the
correct C-terminally cleaved FL8 pre-cursor in high quantity, the
+1 and +2 oligopeptide sequences did not generate any C-
terminally cleaved pre-cursor peptides. For the +1 oligopeptide,
the breadth of intra-epitope cleavage was enhanced in comparison
to the original peptide (in which intra-epitope cleavage site was
predominantly focused after the F). For the +2 oligopeptide,
despite repeat analyses, only three fragments were identified in
addition to the mother peptide. This is indicative that the motif
markedly alters both cleavage patterns and the overall quantity of
pre-cursors generated. Collectively, these data demonstrate that
the phenylalanine motif in the N-terminal sequence can diminish
epitope processing, and highlight that even a single virus-isolate
polymorphism (H89P) in the flanking region can substantially alter
epitope production.
Discussion
We have shown that striking differences exist in CTL antiviral
efficacy to a conserved epitope shared between diverse viral
isolates, and that from the panel of HIV-1 isolates only 23% were
recognized by CTL. In experiments with five high titre HIV-
laboratory strains in vitro, FL8-specific CTL demonstrated efficient
viral suppression and a strong IFNc response against endogenous
FL8 peptide presented by cells infected with clade isolate HIV-
193RW024, and clade B HIV-1MN, and sub-optimal antiviral
activity to clade A isolate HIV-192UG029. However, no CTL
antiviral activity was detected against a further two clade B strains,
HIV-1HXB2 and HIV-189.6. We also utilised a recombinant
vaccinia virus system expressing Nef from eight viral isolates,
each from a different group M clade (A–H), to evaluate whether
FL8 epitope-specific CTL recognition and antiviral activity differs
between viral isolates. Again, we observed significant differences in
CTL lysis and IFNc secretion, with correct epitope processing and
CTL recognition completely abolished in three viral isolates (A,
AE and G) and impaired in a further four isolates (B, C, F, H).
Collectively, we demonstrate that a surprisingly large proportion
(77%) of Nef proteins with a conserved FL8 epitope, expressed by
HIV-1 isolates or as recombinant vaccinia-Nef were suboptimally
recognised by FL8- specific T-cells, despite the presence of the
same epitope. Both endogenous expression systems clearly show
that the antiviral efficacy of CD8+ T cells to an invariant epitope is
heavily dependent on the infecting viral isolate, which occurs
independently of clade-grouping. We have shown that inter-clade
and intra-clade polymorphisms in the FL8 flanking region
modulate epitope processing by the immunoproteasome, to
enhance or impair epitope generation, which is associated with
altered CTL recognition and antiviral activity in the infecting
HIV-1 strains tested. Furthermore, we demonstrate that the
‘swapping’ of the flanking regions between viruses that are
recognised and not recognised can appreciably modulate epitope
processing, and we identify a N-terminal phenylalanine motif that
can diminish epitope generation. When modified, this can help to
optimize CTL responses elicited by appropriately designed vaccine
vectors containing critical flanking sequences in addition to the
epitope that enhance epitope antigenicity.
Although it has been previously shown that flanking residues
can impact epitope presentation by MHC, also for HIV-1 derived
epitopes [19,23] such studies have focused on identifying amino
acid variation predominantly within a single viral isolate. In
contrast, our study evaluated the reason for variable CTL
responses despite absolute conservation of a HIV Nef epitope
shared by a panel of 13 HIV-1 whole viral isolates and
recombinant vaccinia-Nef. Strikingly, our results strongly suggest
that the impact of viral variation on efficient antigen processing
has been seriously underestimated, and this has been reinforced by
a reliance on peptide-based assays to measure T-cell responses in
natural history and vaccine studies. Due to the current focus on
developing HIV vaccines that elicit T-cells to conserved regions of
the viral genome, this is an important finding that has implications
for both vaccine design and evaluation of vaccine efficacy.
Our results emphasise that the antiviral efficacy and cross-
reactive potential of CD8+ T-cells should be assessed by their
ability against cells infected with virus, and it cannot be accurately
predicted solely on the basis of epitope conservation or based on
the results of CTL assays using exogenously-loaded peptides. Since
infecting viral isolates can exploit impaired antigen processing and
presentation to hide from immune surveillance, epitope conserva-
tion between viruses may not accurately predict the cross-reactive
potential and antiviral efficacy of CTL. The lack of epitope
presentation in particular viral backbones may be one of the
reasons that high levels of CTL elicited in people who become
super-infected, either after stable HIV-1 infection [43] or after
vaccination [44], appear to be ineffective even when the infecting
virus contains the identical epitope. Our data suggest that
potential immunogens for cross-clade vaccine design should not
be based solely upon invariant epitopes, but should focus upon
conserved regions that include similar epitope flanking regions
which have been tested via functional assays for endogenous
presentation prior to use in vaccine constructs. Similarly, it will be
important to measure the ability of vaccine elicited T cells to
recognize a range of different virus isolates in whole-virus assays as
well as the more conventional peptide-based studies. The use of
whole-virus assays is not only informative on the efficacy of antigen
processing and presentation, but can also be adapted to detect
additional changes in CTL antiviral efficacy attributable to viral
functions; which include differential protein expression kinetics,
variation in protein expression levels by Tat, and the down-
regulation of MHC class I by Nef [31]. For future vaccine design,
it may also be necessary to reassess the relative value of utilising
particular highly conserved and immunogenic regions of the virus,
such as this FL8 epitope or the Gag p24 region [10,45], since
sequence conservation may mask a lack of presentation that
undermines the efficacy of vaccine-induced responses. Interest-
ingly, since Gag is much less variable between HIV-1 primary
isolates and also during the natural course of infection due to
fitness costs associated with changes in sequence [46], the
probability of gag epitopes being processed more efficiently
among diverse viral isolates may be higher than for epitopes from
other HIV proteins. This could potentially contribute to the
efficacy of Gag-specific CTL observed in chronic HIV-infected
patients [47].
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also shape immunodominance as the targeting of HIV-specific
CTL epitopes in a hierarchical pattern is sensitive to alterations in
antigen processing and presentation [48]. FL8 is a well
characterised immunodominant epitope during acute infection,
with FL8-specific T-cells detected in over 70% of HIV-infected
HLA-B8 participants tested [49]. Yet, immunodominance does
not necessarily mean that the FL8 epitope is optimally processed in
the majority of viral strains within each infected individual. The
low antigen load generated by a viral isolate with sub-optimal or
impaired epitope processing may be sufficient to prime T-cells, but
insufficient to trigger cytotoxic killing in vivo, especially by low
avidity CTL. In addition to the impact of viral isolate-specific
polymorphisms, the high mutation rate of HIV may give rise to
potential intra-epitopic and epitope-flanking escape mutations
during acute infection [50] that subsequently diminish processing.
Therefore, the T cells primed by the infecting virus might not be
able to control mutated viruses that emerge during the course of
infection. Also, strong immune pressure upon neighbouring
epitopes such as B57-KF9 Nef in the first few weeks post-infection
[13] or on epitopes overlapping with FL8, such as B60-KL9 [51],
A2-FL11, A3-AK9, A3-DK9, A24-HL9, may alter the generation
and consequent immunogenicity of FL8. Furthermore, in the
absence of sufficient antigen, where cells are infected by non-
infectious virus or epitope processing is abolished, dendritic cells
may acquire these HIV-infected targets and successfully cross-
present HIV antigens to prime the expansion of HIV-specific T-
cells [52]. Collectively, these mechanisms may explain why FL8-
Figure 9. Critical phenylalanine residues in the N-terminal FL8 flanking region diminish epitope generation. (A) Replacing the N-
terminal flanking region of HIV-192UG029 with the one of HIV-192UG037 generating a ‘‘hybrid’’ FL8 epitope precursor abolishes the correct C-terminal
processing of the FL8 epitope. All three 25-mer oligopeptides representing HIV-194UG129 (left panel), HIV-192UG037 Nef82–106 (right panel) and the
‘‘hybrid’’ epitope precursor (middle panel) were incubated with purified immunoproteasome for 0, 10, 40 and 70 minutes, and the resulting peptide
fragments were identified using tandem mass spectrometry. Peptide fragments with an individual ions score .30 are shown for immunoproteasomal
digests analysed at 70 minutes. The cleavage sites within each peptide sequence are indicated by black arrows, with bold arrows indicating frequent
cleavage. The conserved FL8 epitope sequence is highlighted in red and virus-specific polymorphisms in the FL8 flanking region are highlighted in
blue. (B) Phenylalanine substitutions at position 89 and 85 in HIV-192UG029 abolished C-terminal processing of the FL8 epitope. MS based analysis of
resulting peptide fragments were performed as described in (A).
doi:10.1371/journal.ppat.1001341.g009
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other responses, FL8 is an outlier that does not correlate with viral
control at set point [53].
In our study, we have used rVV in addition to whole HIV to
demonstrate our major conclusion that the anti-viral efficacy of
B8 FL8 restricted responses are heavily dependent on viral
isolates. Since the backbones for rVV and whole virus are
different, it is possibile that rVV may not fully represent whole
virus, and vaccinia expression levels and HIV expression levels
are not equivalent. Ideally, direct HIV to HIV comparison
would be very useful for the hypothesis. However, it is worth
noting that the ELISPOT by using live virus (MN) infected cells
or Vaccinia virus(MN) both give detectable FL8-specific
responses which is indicative that the two assays are comparable.
Processing data by using the sequences derived from rVV
further confirmed the initial observation utilising rVV in IFNc
ELISPOT and lytic assays. Interestingly, analysis of viral amino
acid sequence (arising from PCR amplification and sequencing
of our infected targets) consistently differed from the expected
Los Alamos National Laboratory (LANL) HIV Sequence
Database for each of the five viruses, although the FL8 epitope
remained unchanged. Whilst some of the viruses used in our
assays were molecular clones, others were clinical isolate
swarms, and therefore we could not exclude the possibility that
there is heterogeneity in the FL8 epitope or flanking sequences.
Yet consistent sequencing results were obtained when multiple
PCR were performed, suggesting sequences showed in table 1
were dominant sequences. Considering that HIV undergoes an
average of 1 mutation per genome per replicative cycle due to
the error-prone nature of the reverse transcriptase, some
mutations may become ‘fixed’ or continue to evolve in in vitro
assays in which CD4+ T-cells are infected with HIV-1
laboratory strains, even under no selection pressure. Due to
this high mutation rate, the LANL database represents a ‘snap
shot’ of viral genomes and proteomes at a single time point, and
therefore repeated sequencing is necessary.
Our in vitro digests utilised immunoproteasomes as they are
typically induced within the first day of viral infection by
exposure to IFNc or TNFa [54] [55]. Although immunoprotea-
somes can generate a different spectrum of epitopes from
standard 20S proteasomes, the effects are thought to be relatively
subtle, with more pronounced quantitative rather than qualitative
differences [56]. Current estimates suggest that only 15% of
peptides are the appropriate 8–11mer length for MHC-loading
after proteasomal or immunoproteasomal digestion [57], there-
fore the generation of extended FL8 precursors is not unusual.
The N-terminal extensions are usually trimmed by aminopepti-
dases in the cytosol or after TAP-mediated transfer into the ER
[58], although successful CTL recognition of an endogenously
derived 15-mer N-terminally-extended HIV-1 gp160 peptide was
recently observed [59]. Since more than 99% of peptides are
thought to be destroyed by cytosolic peptidases before encoun-
tering TAP [60], a limitation to this technique is that the
liberation of FL8-containing precursors in our in vitro assays
cannot guarantee efficiency in subsequent processing and
presentation steps of FL8. However, the importance of the
proteasome in liberating Nef peptides, and the strong correlation
between the identities of extended epitopic precursors generated
via in vitro proteasomal cleavage and naturally processed peptides
acid-eluted from the surface of Nef-transfected cells, indicate that
in vitro digests are a reliable tool [38,61]. These studies on Nef,
together with our in vitro inhibition assays and immunoproteaso-
mal digestions, strongly support the central role of the protea-
some and immunoproteasome in altering peptide generation. In
addition, since the specificity of TAP transport, ERAAP trimming
and also HLA-binding affinity are dictated by internal epitope
composition, particularly the C-terminal residue [37], they are
likely to be similar between viral strains with a conserved epitope
(post-proteasomal proteolysis). Therefore, these steps further
along in the processing pathway are expected to have limited
influence on the generation of the conserved FL8 epitope studied
here, although this warrants further investigation. Interestingly,
the overlapping HLA-B*60 KL9 epitope (KEKGGLEGL) is
flanked by the amino acids FL at the N-terminus [49], and the
FL8 epitope (FLKEKGGL) is flanked by SH. These differences
can be sufficient to determine a completely different outcome in
their processing efficiency by the proteasome.
In conclusion, our findings show that striking differences exist in
the antiviral efficacy of CTL to an invariant epitope shared
between viral isolates. Only a small proportion (23%) of the HIV-1
Nef proteins, expressed by HIV-1 isolates or as recombinant
vaccinia-Nef, elicited optimal FL8-specific CTL antiviral respons-
es, whilst the majority demonstrated impaired or completely
abolished epitope processing. We found that virus-specific
polymorphisms in the flanking region to a conserved epitope
substantially alters immunoproteasomal proteolysis, favouring,
impairing or completely abolishing epitope generation, which is
correlated with the efficiency of CTL antiviral activity in vitro and
may play an important role in determining epitope immunoge-
nicity and immunodominance required to prime T-cells in vivo.
CTL antiviral efficacy is heavily dependent on the infecting viral
strain; this occurs independently of clade-grouping. This is of
major relevance for the design of future vaccines protective against
genetically diverse strains of HIV-1, and should be carefully
evaluated when assessing the effectiveness of vaccine-induced T-
cell responses.
Materials and Methods
Viruses
HIV-1 viral isolates 92UG029, 93RW024 (clade A) were
obtained from The UNAIDS Network for HIV Isolation and
Characterization, and the DAIDS, NIAID. HIV-1 laboratory
strains IIIB, MN, 89.6 (clade B) were obtained from the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, in addition to eight recombinant vaccinia viruses
expressing Nef protein from different group M clades (specified
within brackets): HIV-192UG037.1(A), HIV-1MN (B), HIV-196ZM651
(C), HIV-194UG114.1 (D), HIV-1CM235-32 (AE), HIV-193BR020 (F),
HIV-192NG83.2 (G) and HIV-190CF056 (H). Details and acknowl-
edgment of each reagent are listed in supplemental material.
CTL clones and HIV-1 permissive target cells
CTL clones specific for HLA-B8 epitopes were generated by
limiting dilution from the PBMCs of HIV-infected patients
responding to the FL8 and EI8 epitope and maintained as
described in Dong et al 2004 [62]. The Human T cell leukaemia
C8166 line stably expressing CD4+ and HLA-B8 was maintained
in R10 media (RPMI 1640 with 100 U/ml of penicillin, 100 U/
ml of streptomycin, 2 mM L-glutamine and 10% heat-inactivated
fetal calf serum from Sigma-Aldrich).
CTL lysis assays
CTL lysis assays were performed using standard
51Chromium
release assays as described elsewhere [63]. Slight modifications
were made to test infection with recombinant vaccinia viruses
(rVV). In brief, a B-cell line (BCL) expressing HLA-B8 was
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CO2, then washed extensively prior to infection with rVV
encoding HIV-nef genes at 2610
6 pfu/million cells for one hour
in serum-free RPMI. Infected cells were allowed to recover for a
further two hours in R10. The labeled target cells were transferred
to a round bottom 96-well plate and co-cultured with HLA-
matched CTL clones in triplicate at an E:T ratio of 40000:5000
per well for a further 4 hours at 37uC. Supernatants were
harvested and radioactivity was assessed using a beta-plate counter
(Wallac). Spontaneous chromium release was determined by
analysing the release from target cells incubated in R10 media
and maximum release of incorporated chromium was obtained
from target cells treated with 5% Triton X-100 detergent. Specific
lysis was calculated=100 6 (experimental lysis 2 spontaneous
lysis)/(maximum lysis 2 spontaneous lysis).
Human IFNc Elispot assay
Standard Human IFNc ELISPOT assays were performed as
described elsewhere [62]. Slight modifications were made when
testing recombinant vaccinia viruses (rVV). In brief, a HLA-B08
expressing BCL was infected with rVV encoding HIV-nef genes at
2610
6 pfu/million cells for one hour in 1 ml RPMI and recovered
as described above. Subsequently, the infected target cells were
washed twice and added to pre-coated IFNc ELISPOT plates with
a HLA-matched CTL clone at an E:T ratio of 400:20,000, in
triplicate, in a final volume of 100 m/well. Control wells included
uninfected BCL (negative) and peptide pulsed uninfected BCL
(positive) plus peptide pulsed rVV-infected BCL co-cultured with
CTL. Assays were incubated for 6 hours at 37uC/5% CO2 and
developed as normal.
Live virus ELISPOT (LVE)
Differing HIV-1 strains (2-fold TCID50) were used to infect
C8166 cells. Infected cells were washed twice, split with at least
1610
6 cells/T25 flask cultured in a total volume of 2 ml R10 for a
period of 6, 24, 48, 72 and 96 hours post-infection at 37uC/5%
CO2. At each time point, cells were washed, counted and co-
cultured with the panel of HLA-matched CTL clones in triplicate
at one E:T ratio of 400:20000 on the pre-coated interferon gamma
IFNc ELISPOT plates at a final volume of 100 ml/well. Negative
controls included the individual CTL clones co-cultured with
uninfected target cell line in triplicate, and positive control
included each CTL clone co-cultured with uninfected target cells
pulsed with 2 mM of specific peptide. ELISPOT plates were
incubated for 6 hrs at 37uC/5% CO2 and subsequently washed
and developed as described previously. Spot forming units (SFUs)
were counted using the ELISPOT reader system AID ELIspot 4.0.
Viral suppression assay (VSA)
Differing high titre HIV-1 strains (TCID50) were used to infect
the C8166 cell pellets during a 90 minute incubation at 37uC/5%
CO2 and were subsequently washed (26) to remove free virus.
5610
4 infected cells were co-cultured with HLA-matched HIV-1
specific CTL clones at differing E:T ratios of 1:1, 1:2, 1:4, 1:8 &
1:16 in H10-IL2 (200 U/ml) on a flat bottom 96-well plate, in a
final volume of 200 ml per well, at 37uC for 4 days. Each condition
was performed in triplicate, including one HLA-mismatched clone
as a negative control and virus-infected cells in the absence of CTL
as a positive control. Suppression of infected cells by CTL on Day
4 was directly monitored using an intracellular anti-p24 gag mAb
(KC57-RD1, Beckman Coulter). The extracellular p24 content in
the supernatant was also assayed by quantitative p24 antigen
ELISA (Immunodiagnostics) in accordance with the manufactur-
er’s protocol.
Proviral DNA isolation and sequencing
Proviral DNA was isolated for each high titre virus from control
wells containing only HIV-infected C8166 cells in the viral
suppression assay using the PureGene DNA isolation Kit (Gentra
Systems) as per the manufacturer’s instructions. Nef was amplified
from proviral DNA by nested PCR. The nested PCR amplifica-
tion was carried out in a total volume of 50 ml using the Taq
polymerase PCR reaction kit (QIAGEN) and AccuPrime Taq
DNA Polymerase High Fidelity kit (Invitrogen), according to the
manufacturer’s instructions. GTA GCT GAG GGG ACA GAT
AG and TGC TAG AGA TTT TCC ACA C. Initial denaturing
at 94uC for 120 seconds was followed by 30 cycles of denaturing at
94uC for 30 seconds, annealing at 52uC for 30 seconds and
extension at 72uC for 90 seconds. A final extension at 72uC was
run for 300 seconds. The internal pair of primers used was GAA
GAA TAA GAC AGG GCT and AGG CTC AGA TCT GGT
CTA A. Initial denaturing at 94uC for 120 seconds was followed
by 30 cycles of denaturing at 94uC for 30 seconds, annealing at
56uC for 30 seconds and extension at 72uC for 90 seconds, with a
final extension at 72uC was run for 300 seconds. The PCR
products were checked for size on a 1% agarose gel and
sequencing was performed in the MRC HIU Sequencing Facility,
Weatherall Institute of Molecular Medicine.
Flow cytometry for HLA-B8 surface expression
1 million C8166 were infected separately with the five high titre
viruses (TCID50) for 48 hours whilst 1 million BCL were infected
separately with the eight rVV (2610
6 pfu/million targets) for four
hours. Both sets of virus-infected cells were stained with a biotin-
conjugated anti-HLA-Class I B8 monoclonal antibody (AB33716,
Abcam) washed twice, and fixed with 1% paraformaldehyde.
HLA-B8
2 negative cells were used to set the negative quadrants
and to confirm negligible cross-reactivity of the antibody to other
HLA-alleles expressed on target cells. Additional controls included
the biotin-conjugated antibody in the presence and absence of
streptavidin and uninfected cells. At least 10
5 live cells per
infection were counted using a Cyan flow cytometer and analysed
with FlowJo.
Intracellular antigen processing inhibition assays (IAPIA)
The C8166 cells were pre-treated with proteasome inhibitor
Epoxomicin, TPP II inhibitor AAF-CMK and aminopeptidase
inhibitor Bestatin (all Biomol) at varying concentrations at 37uC
for one hour prior. The cells were then infected with HIV-
192UG029 at TCID50 for 90 minutes at 37uC/5% CO2. Two
controls comprising pre-treated cells not infected with HIV (to
determine the affect of the inhibitor on cell survival in the absence
of HIV-induced cell death), and HIV infected untreated cells (to
determine the maximum response elicited in the absence of
inhibitor treatment) were used. All cells were washed after
90 minutes and transferred to a T25 flask containing R10 medium
for 36 hrs before being used as targets in a modified Live Virus
Elispot with a FL8-specific CTL clone at an E:T ratio of
400:20000 as described previously. Slight modifications were
made to test infection with recombinant vaccinia virus (rVV)
expressing Nef from HIV-1 clade D isolate HIV-194UG114.I n
brief, BCL expressing HLA-B08 was incubated with 150 mCi of
chromium for one hour at 37uC/5% CO2 and then washed
extensively. The BCL were pre-treated with proteasome inhibitor
Epoxomicin, TPPII inhibitor AAF-CMK and aminopeptidase
inhibitor Bestatin (all Biomol) at varying concentrations in serum-
free RPMI for one hour at 37uC. The cells were then infected with
rVV-Nef-D at 2610
6 pfu/million targets for one hour in serum-
free RPMI, before recovery in R10 for a further one hour. The
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well plate and co-cultured with a HLA-matched CTL clone in
triplicate at an E:T ratio of 40000:5000 per well for a further
4 hours at 37uC. Supernatants were harvested and radioactivity
was assessed as described previously.
Proteasomal digestion assay (PDA)
Four 25-mer oligopeptides were designed to cover the FL8
epitope and flanking regions corresponding to the amino acid
sequence as determined by sequencing for HIV-1HXB2IIIB, HIV-
192UG029 and HIV-192UG037 and hybrid viral sequences. Extended
peptides
KAALDLSHFLKEKGGLDGLIYSQKR (HIV-1HXB2IIIB),
KGAVDLSHFLKEKGGLDGLIYSRKR (HIV-192UG029),
KAAFDLGFFLKEKGGLDGLIYSKKR (HIV-192UG037),
KAAFDLGFFLKEKGGLDGLIYSRKR (HIV-192037N-029C),
KGAVDLSFFLKEKGGLDGLIYSRKR) (HIV-192UG029+1),
KGAFDLSFFLKEKGGLDGLIYSRKR) (HIV-192UG029+2):
containing the HLA-B8 restricted FL8 epitope FLKEKGGL
(indicated in bold) were synthesized by solid-phase F-moc
chemistry on an automated peptide synthesizer (Advanced
ChemTech) and purified to .98% by reversed-phase HPLC. In
vitro proteasomal digestion of synthetic 25mer oligopeptides was
conducted using immuno-20S (i20S) proteasome purchased from
Biomol International, essentially as described [64]. For each
oligopeptide, 1 mg of immuno-20S proteasome was incubated with
10 mg of peptide in a final volume of 100 mL of 20 mM Hepes,
pH 7.8, 2 mM magnesium acetate and 2 mM dithiothreitol and
incubated at 37uC/5% CO2. Sample aliquots were taken at
several time points (0, 10, 40, 70 minutes) and reactions were
terminated by the addition of 0.1 volume of formic acid (FA).
Control reactions without the i20S-proteasome were analysed to
evaluate non-specific peptide degradation. The i20S-proteasome
was pelleted by ultracentrifugation at 100000 g for 5 hours, and
supernatants containing digested peptides were analysed using
nano UPLC-high/low collision energy switching MS (MS
E)a s
described [65]. In brief, the peptide digests were subjected to
chromatographic separation by a NanoAcquity UPLC system
coupled to a QTof premier tandem mass spectrometer (Waters,
Milford, MA, USA). For peptide precursor and fragment
identification and simultaneous quantification, the instrument
was run in MS
E mode. Peptide peaks corresponding to the original
undigested and shorter peptide fragments resulting from immu-
noproteasomal digestion were identified using a MASCOT search
engine (version 2.2) and a custom made database containing HIV-
peptide sequences. Quantitative information was obtained from
extracted ion chromatograms using MassLynx 4.1 software.
Supporting Information
Figure S1 The viruses utilized in our assays are not Nef deficient
and Nef expression levels are similar. High titre viruses HIV-
1HXB2 (A), MN (B) and 92RW024 (C) have a conserved Nef A24-
RW8 epitope that induces strong RW8-specific CTL responses in
Live Virus Elispots. Recombinant vaccinia-viruses rVV-A, -AE
and -G have a conserved Nef A3-QK10 epitope that elicits CTL
antiviral activity in a lytic chromium release assay (D). HIV-189.6
and UG029 exhibited a defined RW8 intra-epitopic variant at
position two (2F) that is known to result in the loss of CTL
recognition via altered epitope processing.
Found at: doi:10.1371/journal.ppat.1001341.s001 (0.32 MB TIF)
Figure S2 Similar results are observed between the use our
HLA-B8 cell line and primary HLA-B8 CD4+ T-cells when
target-cells were infected separately with HIV-MN (the FL8
epitope was processed) and HIV-IIIB (the FL8 epitope wasn’t
processed). Primary CD4+ T-cells expressing HLA-B8/B7 were
infected separately with HIVHXB2IIIB and HIVMN in a viral
suppression assay (p24 Elisa) with CTL clones specific for the
HLA-B8 Nef FL8 epitope and also CTL clones specific for a HLA-
B7 Nef RL10 epitope as an internal control.
Found at: doi:10.1371/journal.ppat.1001341.s002 (1.28 MB TIF)
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